Rare Bleeding Disorders and Bleeding Disorder of Unknown Cause: Current Understanding and Recent Developments.

Area of Science:

• Hematology
• Genetics
• Internal Medicine

Background:

• Rare bleeding disorders (RBDs) encompass inherited conditions affecting coagulation factors or platelets, like Glanzmann thrombasthenia (GT) and severe factor deficiencies.
• Bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion and the most common finding in patients with lifelong bleeding tendencies.
• Clinical presentation of BDUC is highly variable and often poorly predicted by standard laboratory results.

Purpose of the Study:

• To review current understanding and recent developments in four representative bleeding disorders: inherited platelet function disorders (IPFDs) including GT, fibrinogen disorders, factor XI (FXI) deficiency, and BDUC.
• To identify common priorities for improving diagnosis and management across these conditions.

Main Methods:

• State-of-the-Art review summarizing current knowledge and recent advancements.
• Focus on four specific bleeding disorders: IPFDs (highlighting GT), fibrinogen disorders, FXI deficiency, and BDUC.
• Analysis of diagnostic challenges, management complexities, and potential improvements.

Main Results:

• Management of IPFDs is challenging due to variable bleeding severity and specialized care needs.
• Limited assay availability hinders consistent classification and management of fibrinogen disorders.
• FXI deficiency shows a weak correlation between factor levels and bleeding phenotype, emphasizing individualized care.
• BDUC shares overlaps with mild inherited disorders; global hemostatic assays can improve diagnostic precision.

Conclusions:

• Harmonizing diagnostic approaches, strengthening international registries, and integrating patient-reported outcomes are crucial priorities.
• Improved diagnostic precision for BDUC and other rare bleeding disorders is achievable through advanced assays and standardized methods.
• Individualized patient care is essential, particularly in conditions like FXI deficiency where factor levels do not reliably predict bleeding risk.